Overview

A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia

Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to assess the continued safety of the daily coadministration of ABT-335 in combination with rosuvastatin calcium, simvastatin or atorvastatin calcium.
Phase:
Phase 3
Details
Lead Sponsor:
Abbott
Treatments:
Atorvastatin
Atorvastatin Calcium
Calcium
Calcium, Dietary
Fenofibric acid
Rosuvastatin Calcium
Simvastatin